NovAliX will use its Graffinity SPR-based screening platform in a drug discovery program of Teijin Pharma. NovAliX will use the technology to identify novel chemotypes, and then apply its native nano-MS technology to further characterize selected small molecule hit structures.
Under the multitarget drug discovery collaboration, French-owned NovAliX said it will receive technology access fees as well as further research funding payments from the collaboration, its first with Teijin but its second with a Japanese pharmaceutical company.
NovAliX-owned Graffinity Pharmaceuticals announced in March 2011 that it would apply the fragment based screening platform to a drug discovery program of Shionogi & Co., in return for unspecified technology access fees and payments.